Results 1 to 10 of about 597 (116)

Comparative therapeutic efficacy of interferon alfa-2b and combination lopinavir/ritonavir plus interferon alfa-2b against SARS-CoV-2

BMC Infectious Diseases, 2021
Background The outbreak of coronavirus disease 2019 (COVID-19) posed an enormous threat to public health. The use of antiviral drugs in patients with this disease have triggered people’s attentions.
Jingyuan Liu, Chunjing Du, Lin Pu, Pan Xiang, Haofeng Xiong, Wen Xie, Zhihai Chen, Ang Li   +7 more
doaj   +1 more source

Interferon-alpha induced obsessivecompulsive disorder in a patient with Hepatitis-C

Psychiatry and Clinical Psychopharmacology, 2021
Interferon alpha (IFN- α) is commonly used in the treatment of viral hepatitis because of its stimulating effects on the immune response. While psychiatric adverse effects such as depression, mania or psychosis that arise during interferon alpha ...
Selma Bozkurt Zincir, Filiz Izci, Ahsen Eratalay, Umit Basar Semiz   +3 more
doaj   +1 more source

Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource-limited setting. [PDF]

PLoS ONE, 2012
BACKGROUND: To estimate, from the perspective of the Chinese healthcare system, the economic outcomes of five different first-line strategies among patients with metastatic renal cell carcinoma (mRCC).
Bin Wu, Baijun Dong, Yuejuan Xu, Qiang Zhang, Jinfang Shen, Huafeng Chen, Wei Xue   +6 more
doaj   +1 more source

Interferon-alfa in the management of cystic craniopharyngioma in children under 5 years of age

Archives of Pediatric Neurosurgery, 2021
Introduction: the best therapeutic option for the management of craniopharyngioma in younger children remains controversial, ranging from complete surgical resection, partial surgical resection associated with radiotherapy and application of ...
Jose Roberto Tude Melo, Felipe Reynan Paiva Vieira Santos, Igor Campos da Silva, José Henrique Silva Barreto   +3 more
doaj   +1 more source

Importance of adherence for efficacy of hepatitis C combined therapy [PDF]

Srpski Arhiv za Celokupno Lekarstvo, 2013
Introduction. Dual antiviral therapy with pegylated interferon alfa-2a and ribavirin leads do sustained elimination of hepatitis C virus infection in over 50% patients with genotypes 1 and 4 and in over 80% with genotypes 2 and 3.
Nožić Darko, Delić Dragan, Božić Milena, Fabri Milotka, Svorcan Petar, Konstantinović Ljiljana   +5 more
doaj   +1 more source

A Phase 3 clinical trial validating the potency and safety of an innovative, extra‐long‐acting interferon in chronic hepatitis C

JGH Open, 2022
Background and Aim Ropeginterferon alfa‐2b is a novel mono‐pegylated, extra‐long‐acting interferon. It is administered infrequently and showed good tolerability and clinical activity for the chronic hepatitis B or C treatment in our previous Phase 2 ...
Chi‐Yi Chen, Wan‐Long Chuang, Albert Qin, Wen‐Hua Zhang, Li‐Ying Zhu, Guo‐Qiang Zhang, Jyh‐Jou Chen, Ching‐Chu Lo, Xinmin Zhou, Xiaorong Mao, Jia Shang, Hsing‐Tao Kuo, Wen Xie, Chien‐Hung Chen, Gin‐Ho Lo, Dae W Jun, Shuangsuo Dang, Chan‐Yen Tsai, Ting‐Fang Wang, Hsin‐Hui Lai, Kuan‐Chiao Tseng, Yi‐Wen Huang, Pei‐Jer Chen   +22 more
doaj   +1 more source

Modern opportunities of interferons in treatment of children with COVID-19

Медицинский совет, 2021
Introduction. In 2020, most doctors were at the frontlines in the fight against the novel coronavirus infection (COVID-19). In the process of searching for effective etiotropic drugs, news came in that type I interferons had been successfully used for ...
Asiya I. Safina, Olga V. Sharipova, Ildus Ya. Lutfullin, Olga S. Naumova, Maria A. Daminova   +4 more
doaj   +1 more source

Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: Analysis of Mexican patients included in a multicenter international clinical trial

Annals of Hepatology, 2003
Treatment with polyethylene glycol-modified interferon alfa-2a (peginterferon) alone produces significantly higher sustained antiviral responses than treatment with interferon alfa-2a alone in patients with chronic hepatitis C virus (HCV) infection.
Francisco Bosques-Padilla, MD, Rafael Trejo-Estrada, MD, Octaivio Campollo-Rivas, MD, Carlos Cortez-HernÁndez, MD, Margarita Dehesa-Violante, MD, Héctor Maldonado-Garza, MD, Raúl Pérez-Gómez, MD, Armando Cabrera-Valdespino, MD   +7 more
doaj   +1 more source

SIDE EFFECTS OF VARIOUS SCHEMES OF INTERFERON THERAPY OF CHRONIC HEPATITIS C AND THEIR CORRECTION

Медицинский совет, 2017
The aim of this work was to assess the frequency and severity of major interferon-induced side effects depending on the applied interferon drug. The study included 29 patients with chronic hepatitis C with genotype 1b, 2, 3a/b.
A. M. Ryumin, O. L. Sobolevskaya, O. V. Korochkina   +2 more
doaj   +1 more source

Daily interferon induction regimen using different manufactured interferons (alpha-2a or alpha-2b) in combination with ribavirin for treatment of chronic hepatitis C: a prospective randomized study Esquema de indução diário com interferon alfa 2-a ou alfa 2-b em combinação com ribavirina para tratamento da hepatite crônica C: estudo prospectivo randomizado

Arquivos de Gastroenterologia, 2006
BACKGROUD: Studies on hepatitis C virus kinetics showed that serum levels of interferon fall 48 h after drug administration, when viral load is increasing again.
Eduardo Lorens Braga, André Castro Lyra, Lourianne Nascimento, Eduardo Netto, Luciano Kalabrik, Luiz Guilherme Costa Lyra   +5 more
doaj   +1 more source